<DOC>
	<DOCNO>NCT01035658</DOCNO>
	<brief_summary>In study , patient relapse refractory ovarian cancer receive treatment pazopanib liposomal doxorubicin ( Doxil ) disease progression unacceptable toxicity occur . The Phase I portion define dose limit toxicity ( DLT ) pazopanib liposomal doxorubicin administer combination . Once maximum tolerate dose identified Phase I portion , Phase II portion evaluate efficacy safety combination patient population .</brief_summary>
	<brief_title>Study Pazopanib Doxil Patients With Advanced Relapsed Platinum-Sensitive Platinum-Resistant Ovarian , Fallopian Tube Primary Peritoneal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis epithelial ovarian carcinoma ( FIGO Stage II IV ) , primary peritoneal cancer fallopian tube . 2 . One 2 previous chemotherapy regimen advance ovarian cancer . At least one regimens must contain platinum agent . 3 . Patients platinumresistant ( relapse &lt; 6 month complete platinumcontaining regimen ) platinum sensitive ( relapse ≥ 6 month platinumcontaining regimen ) eligible . 4 . Radiographically documented progression per RECIST criterion ( version 1.1 ) progression CA125 subsequent last chemotherapy regimen . 5 . Measurable disease ( RECIST criterion ) evaluable disease elevate CA125 level . Patients normal CT scan elevate CA125 level indication disease eligible . ECOG performance status 0 1 . 6 . Normal leave ventricular ejection fraction ( LVEF ) accord institutional standard . 7 . Adequate recovery recent surgery . At least 1 week must elapse time minor surgery ( exception portacath placement ) ; least 4 week must elapse time major surgery . 8 . Laboratory value follow : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥9g/dL . Patients may receive RBC transfusion within 7 day screen assessment . Platelets ≥100,000/L AST ALT must &lt; 2.5 x ULN ( concomitant elevation bilirubin AST/ALT &gt; 1.0 x ULN permit ) . Total bilirubin &lt; 1.5 x institutional ULN ( Gilberts syndrome , direct bilirubin ≤1.5 x ULN ) International normalize ratio ( INR ) 1.2 activate partial thromboplastin time ( aPTT ) 1.2 ULN ( except patient receive anticoagulation therapy ) Cr ≤ 1.5 x ULN . If Cr &gt; 1.5 x ULN , calculate creatinine clearance must ≥50 mL/min Urine protein creatinine ( UPC ) ratio ≤1.0 screening OR Urine dipstick proteinuria &lt; 2+ ( patient discover 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; 1g protein 24 hour eligible ) . 9 . Patients must 18 year age . 10 . Life expectancy ≥12 week . 11 . Patient must accessible treatment followup . 12 . Patients must able understand investigational nature study give write informed consent prior study entry . 13 . Females nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : hysterectomy , bilateral oophorectomy , bilateral tubal ligation , postmenopausal . Patients use hormone replacement therapy ( HRT ) must experience total cessation menses ≥1 year ≥45 year old , questionable case , follicle stimulate hormone ( FSH ) value &gt; 40 mIU/mL estradiol value &lt; 40pg/mL . Patients use HRT must experience total cessation menses ≥1 year ≥45 year old , document evidence menopause base FSH estradiol prior initiation HRT . 14 . Women childbearing potential must negative serum urine pregnancy test perform ≤14 day prior start treatment . Women childbearing potential must use effective birth control measure treatment . Acceptable contraceptive method include : 1 ) intrauterine device document failure rate ≤1 % per year , 2 ) vasectomize partner sterile prior patient‟s entry sole sexual partner female , 3 ) abstinence 14 day prior study entry , throughout dose period , least 21 day last dose protocol therapy , 4 ) doublebarrier contraception , 5 ) oral contraception . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 1 . Patients may receive either investigational marketed agent , act primary antiangiogenic mechanism ( i.e . bevacizumab ) . 2 . Prior treatment liposomal doxorubicin . 3 . Patients brain metastasis . ( Baseline imaging require clinically indicate ) . 4 . Patients know endobronchial lesion and/or lesion infiltrate major pulmonary vessel . 5 . Patients hemoptysis within 6 week first dose study drug . 6 . Patients pregnant breast feed . 7 . Impaired cardiac function include follow condition within past 6 month : NYHA Class II , III IV heart failure . QTc prolongation significant ECG abnormality . Myocardial infarction unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease History sustain ventricular tachycardia . 8 . Patients must take potent CYP3A4 inhibitor &lt; = 14 day prior enrollment include limited : • ketoconazole , itraconazole , troleandomycin , clarithromycin , erythromycin , ritonavir , indinavir , nelfinavir , saquinavir , amprenavir , nefazodone , fluvoxamine , diltiazem , verapamil , mibefradil , cimetidine , cyclosporine , grapefruit juice . 9 . Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 180 diastolic BP &gt; 100mm Hg ) uncontrolled cardiac arrhythmia ( Patients hypertension control antihypertensive therapy eligible . ) 10 . History cerebrovascular accident ( CVA ) , MI within 12 month venous thrombosis within 12 week . ( Patients previous history venous thrombosis stable dose anticoagulation allow . ) 11 . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit safety compliance study requirement . 12 . Inability swallow whole tablet . 13 . Impairment gastrointestinal function gastrointestinal disease may significantly alter drug absorption ( e.g. , active inflammatory bowel disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome significant small bowel resection ) . 14 . Mental condition would prevent patient comprehension nature , risk associate , study . 15 . Use nonapproved investigational agent &lt; = 30 day prior administration first dose study drug . Patients may receive investigational anticancer treatment participate study . 16 . Past current history neoplasm entry diagnosis exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone DFS &gt; = 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>Doxil</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Advanced relapse</keyword>
	<keyword>platinum-sensitive</keyword>
	<keyword>platinum-resistant</keyword>
</DOC>